復星醫藥(02196.HK)擬設立河南復健 加強大健康產業佈局
格隆匯4月25日丨復星醫藥(02196.HK)公告,於2025年4月25日,公司附屬公司復星平耀與上海復健、復星高科技及復曜智港簽訂合夥協議,據此,各方擬共同設立河南復健。河南復健的獲認繳出資總額爲人民幣10.00百萬元,其中:復星平耀(作爲有限合夥人)擬以現金出資人民幣4.90百萬元、上海復健(作爲普通合夥人)擬以現金出資人民幣0.10百萬元、復星高科技(作爲有限合夥人)擬以現金出資人民幣2.90百萬元及復曜智港(作爲有限合夥人)擬以現金出資人民幣2.10百萬元。
爲加強大健康產業的佈局,集團擬參與發起設立以中原地區爲中心,以醫療器械診斷、生命科學、創新藥及其上下遊產業鏈爲主要投資方向的股權投資基金。河南復健設立後,擬作爲發起設立該股權投資基金的普通合夥人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.